Keyphrases
Therapeutic Potential
100%
Moderate to Severe
100%
Active Ulcerative Colitis
100%
Ozanimod
100%
Sphingosine-1-phosphate Receptor (S1PR)
62%
Ulcerative Colitis
50%
Safety Profile
25%
T Cells
12%
Mechanism of Action
12%
Novel Therapeutics
12%
Bradycardia
12%
Lymph Node
12%
Expert Opinion
12%
Treatment Algorithm
12%
Clinical Safety
12%
Gastrointestinal Tract
12%
Clinical Efficacy
12%
Chronic Inflammatory Diseases
12%
Effective Treatment
12%
Pharmacokinetics
12%
Macular Edema
12%
Area Cover
12%
Efficacy Profile
12%
Active Inflammation
12%
Nave
12%
Receptor Subtypes
12%
Functional Antagonist
12%
Side Effect Profile
12%
Lymphocyte Infiltration
12%
Ulcerative Colitis Therapy
12%
Sphingosine-1-phosphate
12%
Dysregulated Immune Response
12%
Oral Small Molecules
12%
Onset of Action
12%
Rapid Onset
12%
Severe Ulcerative Colitis
12%
Lymphocyte Activation
12%
Therapeutic Mechanism
12%
Immune Cell Regulation
12%
Pharmacology, Toxicology and Pharmaceutical Science
Ulcerative Colitis
100%
Ozanimod
100%
Sphingosine 1 Phosphate Receptor
62%
Inflammation
25%
Side Effect
12%
Sphingosine 1 Phosphate
12%
Macular Edema
12%
Clinical Pharmacokinetics
12%
Receptor Subtype
12%